Siemens Medical Systems has received 510(k) clearance from the Food and Drug Administration for its Opdima digital spot mammography unit. Opdima is based on charge-coupled device (CCD) technology and retrofits to the Iselin, NJ, vendor's Mammomat 3000
Siemens Medical Systems has received 510(k) clearance from the Food and Drug Administration for its Opdima digital spot mammography unit. Opdima is based on charge-coupled device (CCD) technology and retrofits to the Iselin, NJ, vendor's Mammomat 3000 mammography system. It has a field-of-view of 49 x 85 mm, which Siemens claims is the largest in the industry among digital spot devices. Siemens launched Opdima in Europe in April (SCAN 4/30/97).
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.